Vanguard Group Inc. Has $1.14 Billion Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Vanguard Group Inc. lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,158,926 shares of the medical research company’s stock after acquiring an additional 60,497 shares during the quarter. Vanguard Group Inc. owned approximately 12.04% of Charles River Laboratories International worth $1,136,938,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fiduciary Financial Group LLC increased its position in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after purchasing an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. M&T Bank Corp increased its holdings in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after buying an additional 66 shares during the last quarter. Cornerstone Investment Partners LLC raised its position in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after acquiring an additional 69 shares in the last quarter. Finally, Metis Global Partners LLC lifted its stake in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 1.6 %

NYSE CRL opened at $155.60 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $7.96 billion, a price-to-earnings ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45. The company has a 50 day moving average of $164.69 and a 200-day moving average of $182.73. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.32.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Barclays dropped their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. Finally, Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $189.77.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).